within Pharmacolibrary.Drugs.ATC.C;

model C04AX33
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.6,
    adminDuration  = 600,
    adminMass      = 0.015,
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Clazosentan is a selective endothelin A (ETA) receptor antagonist developed primarily for the prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). It acts to inhibit vasoconstriction mediated by endothelin-1, thereby improving cerebral blood flow. Clazosentan is approved for use in some regions such as Japan, but not widely approved globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from healthy adult subjects after intravenous dosing.</p><h4>References</h4><ol><li><p>Juif, PE, et al., &amp; Dingemanse, J (2019). Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan. <i>Clinical and translational science</i> 12(5) 440–444. DOI:<a href=&quot;https://doi.org/10.1111/cts.12639&quot;>10.1111/cts.12639</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31004470/&quot;>https://pubmed.ncbi.nlm.nih.gov/31004470</a></p></li><li><p>van Giersbergen, PL, &amp; Dingemanse, J (2007). Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist. <i>European journal of clinical pharmacology</i> 63(2) 151–158. DOI:<a href=&quot;https://doi.org/10.1007/s00228-006-0117-z&quot;>10.1007/s00228-006-0117-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16636870/&quot;>https://pubmed.ncbi.nlm.nih.gov/16636870</a></p></li><li><p>Bruderer, S, et al., &amp; Dingemanse, J (2011). Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan. <i>British journal of clinical pharmacology</i> 71(1) 52–60. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2010.03804.x&quot;>10.1111/j.1365-2125.2010.03804.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21143501/&quot;>https://pubmed.ncbi.nlm.nih.gov/21143501</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AX33;
